Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 186

Sort by

Sort Order Select

Journal Articles

Combining CAR Engineering and CIS Checkpoint Deletion in NK Cells for the Treatment of B Cell Hematologic Malignancies

Blood (2019) 134 (Supplement_1): 1936.

https://doi.org/10.1182/blood-2019-126739

Published: 2019

Journal Articles

CLL Increases the Frequency of CD4 + HLADR + PD1 + T Cells That Demonstrate an Exhaustion Gene Signature and Potential Prognostic Value for Disease Progression

Peter M Henley, BMedSc, Christopher Fegan, MB, MD FRCP, FRCPath, Stephen Man, PhD

Blood (2019) 134 (Supplement_1): 3033.

https://doi.org/10.1182/blood-2019-128546

Published: 2019

Journal Articles

Investigation of Cell-Contact Dependent Alterations in Immune Synapse Formation between T Cells and BCP-ALL Cells

Britta Wenske, PhD, Lothar Marischen, PhD, Julia Welzenbach, André Heimbach, PhD, Per Hoffmann, PhD, Selim Corbacioglu, MD, David A Williams, MD, Anja Troeger, MD

Blood (2019) 134 (Supplement_1): 2754.

https://doi.org/10.1182/blood-2019-128835

Published: 2019

Journal Articles

Blinatumomab-Induced T Cell Activation at Single Cell Transcriptome Resolution

Hong Yin, MD PhD, Yi Huo, PhD, Zhen Sheng, PhD, Chi-Ming Li, PhD, Daniel C Ellwanger, PhD, Daniel Lu, PhD, Oliver Homann, PhD, Songli Wang, MD PhD, Ruibao Ren, MD PhD

Blood (2019) 134 (Supplement_1): 3886.

https://doi.org/10.1182/blood-2019-124636

Published: 2019

Journal Articles

Generation of a Highly Sensitive CD22 CAR

Evangelia K Kokalaki, Biao Ma, PhD, Thomas Grothier, MSc, Warren Hazelton, MSc, Eren Costu, BSc, Somayya Manzoor, MSc, Ram Jha, MSc, Simon Thomas, PhD, Shimobi Onuoha, PhD, Shaun P Cordoba, PhD, Martin Pule, MD

Blood (2019) 134 (Supplement_1): 5747.

https://doi.org/10.1182/blood-2019-128002

Published: 2019

Journal Articles

The IRE1-XBP1s Pathway Impairment Underpins NK Cell Dysfunction in Hodgkin Lymphoma, That Is Partly Restored By PD-1 Blockade

Karolina Bednarska, Jay Gunawardana, PhD, Frank Vari, PhD, Qingyan Cui, PhD, Gayathri Thillaiyampalam, MSc, BSc, Samantha Stehbens, PhD, Sally Mujaj, PhD, Jamie Nourse, PhD, Alexandre Cristino, PhD, Maher K. Gandhi, PhD

Blood (2019) 134 (Supplement_1): 2795.

https://doi.org/10.1182/blood-2019-126372

Published: 2019

Journal Articles

EZH2 Gain-of-Function Mutations Generate a Lymphoma-Permissive Immune Niche

Wendy Béguelin, PhD, Matthew R Teater, PhD, Cem Meydan, PhD, Jude M Phillip, PhD, Ari Melnick, MD

Blood (2019) 134 (Supplement_1): 2768.

https://doi.org/10.1182/blood-2019-132263

Published: 2019

Journal Articles

Ibrutinib-Based Therapy Improves Anti-Tumor T Cell Killing Function Allowing Effective Pairing with Anti-PD-L1 Immunotherapy Compared to Traditional FCR Chemoimmunotherapy; Implications for Therapy and Correlative Immune Functional Data from the Phase III E1912 Trial

Despoina Papazoglou, BSc, Connie E. Lesnick, Victoria Wang, Neil E. Kay, MD, Tait D. Shanafelt, MD, Alan G. Ramsay, BSc,MSc,PhD

Blood (2018) 132 (Supplement 1): 236.

https://doi.org/10.1182/blood-2018-99-118333

Published: 2018

Journal Articles

AMV564, a Bivalent Bispecific (2×2) CD33/CD3 T-Cell Engager, Is Active and Improves Survival in a Mouse Model of Acute Myeloid Leukemia

Linda G Eissenberg, PhD, Julie Ritchey, Michael P. Rettig, PhD, Judith A. Fox, PhD, Jeanmarie Guenot, PhD, John F. DiPersio, MD PhD

Blood (2018) 132 (Supplement 1): 2727.

https://doi.org/10.1182/blood-2018-99-118573

Published: 2018

Journal Articles

Eliciting Anti-Tumor T Cell Immunity in Chronic Lymphocytic Leukemia (CLL) with PD-L1/PD-1 Blockade Is Enhanced By Avadomide Immunotherapy through the Triggering of Immunogenic Interferon Signaling

Nikolaos Ioannou, PhD MSc, BSc, Patrick R. Hagner, PhD, Fadi Towfic, PhD, Anita K. Gandhi, PhD, Kostas Stamatopoulos, MD PhD, Piers E.M. Patten, BSc, MRCP, MRCPath, PhD, Anna Vardi, MD PhD, Alan G. Ramsay, BSc,MSc,PhD

Blood (2018) 132 (Supplement 1): 237.

https://doi.org/10.1182/blood-2018-99-111605

Published: 2018

Journal Articles

Functional Status Is Associated with Outcomes after Allogeneic Stem Cell Transplantation for Older Patients with Hematologic Malignancies

Li-Wen Huang, MD, Chiung-Yu Huang, PhD, Charalambos Andreadis, MD, Aaron C. Logan, MD PhD, Gabriel N. Mannis, MD, Catherine C. Smith, MD, Karin M. Gaensler, MD, Thomas G. Martin, III, MD, Lloyd E. Damon, MD, Michael A. Steinman, MD, Rebecca L. Olin, MD

Blood (2018) 132 (Supplement 1): 3599.

https://doi.org/10.1182/blood-2018-99-112025

Published: 2018

Journal Articles

Myeloma Patient-Derived Bone Marrow Serum Negatively Regulates Natural Killer Cell Activity

Tarun K. Garg, PhD, Katie Stone, BS, Hongwei Wang, MS, Antje Hoering, PhD, Brian A Walker, PhD, Maurizio Zangari, MD, Sharmilan Thanendrarajan, MD, Carolina D. Schinke, MD, Faith E. Davies, MD, Gareth Morgan, MD, Frits van Rhee, MD PhD

Blood (2018) 132 (Supplement 1): 4468.

https://doi.org/10.1182/blood-2018-99-119692

Published: 2018

Journal Articles

Longitudinal High-Throughput T Cell Repertoire Profiling of Chronic Lymphocytic Leukemia Patients Under Different Types of Treatment: Implications for Combination Strategies

Anna Vardi, MD PhD, Elisavet Vlachonikola, Nikolaos Ioannou, PhD MSc, BSc, Fotis Psomopoulos, Konstantia Kotta, Despoina Papazoglou, BSc, Maria Kotouza, Evangelia Koravou, Chrysi Galigalidou, Katerina Gemenetzi, Kostas Pasentsis, Michalis Iskas, Niki Stavroyianni, Achilles Anagnostopoulos, Alan G. Ramsay, BSc, MSc, PhD, Kostas Stamatopoulos, MD PhD, Anastasia Hadzidimitriou, PhD

Blood (2018) 132 (Supplement 1): 4400.

https://doi.org/10.1182/blood-2018-99-118006

Published: 2018

Journal Articles

Thrombin Generation Impairments in Platelet Function Disorders

Justin Brunet, BSc, Subia Tasneem, PhD, Georges E. Rivard, MD FRCPC, Catherine P.M. Hayward, MD

Blood (2018) 132 (Supplement 1): 1150.

https://doi.org/10.1182/blood-2018-99-110247

Published: 2018

Journal Articles

PD-1 Overexpression in Richter's Transformation (RT) and Aggressive Chronic Lymphocytic Leukemia (CLL) after Progression on Ibrutinib Increases Bcl-2 Expression Via Akt/mTOR Pathway

Sutapa Sinha, PhD, Tammy Price-Troska, BS, Shulan Tian, MS, PhD, Charla R Secreto, Xiaosheng Wu, MD, Timothy G. Call, MD, Rong He, MD, Sameer A. Parikh, MD, Saad S. Kenderian, MD, Jose F. Leis, MD PhD, Huihuang Yan, PhD, Karen L Rech, MD, Minetta C Liu, MD, Stephen M. Ansell, MD PhD, Neil E. Kay, MD, Wei Ding, MD PhD

Blood (2018) 132 (Supplement 1): 586.

https://doi.org/10.1182/blood-2018-99-112575

Published: 2018

Journal Articles

Axl-RTK Inhibition Modulates T Cell Functions and Synergizes with Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies

Reona Sakemura, MD PhD, Nan Yang, MD, Michelle J. Cox, Sutapa Sinha, PhD, Mehrdad Hefazi, MD, Michael J. Hansen, Kendall J. Schick, Cynthia L. Forsman, PhD, Justin C. Boysen, Renee C Tschumper, Elizabeth Juarez Diaz, BS, Lars Mouritsen, Jason M Foulks, PhD, Steven L. Warner, PhD, Sameer A. Parikh, MD, Wei Ding, MD PhD, Neil E. Kay, MD, Saad S. Kenderian, MD

Blood (2018) 132 (Supplement 1): 728.

https://doi.org/10.1182/blood-2018-99-112209

Published: 2018

Journal Articles

Modulation of T-Cell Function and Immune Phenotype in the Microenvironment of Emu-TCL1 CLL Bearing Mice By Ibrutinib

Mark-Alexander Schwarzbich, Arantxa Romero-Toledo, MSc, John G. Gribben

Blood (2018) 132 (Supplement 1): 3138.

https://doi.org/10.1182/blood-2018-99-118059

Published: 2018

Journal Articles

Modulation of T-Cell Function in the Microenvironment of Emu-TCL1 CLL Bearing Mice By Btki Appears Independent of ITK

Mark-Alexander Schwarzbich, MD, Arantxa Romero-Toledo, MSc, Melanie Frigault, PhD, John G. Gribben

Blood (2018) 132 (Supplement 1): 3139.

https://doi.org/10.1182/blood-2018-99-116444

Published: 2018

Journal Articles

An expanding network of cytoskeletal defects

Michael D. Keller

Blood (2018) 132 (22): 2316–2317.

https://doi.org/10.1182/blood-2018-10-878603

Published: 2018

Journal Articles

T-cell defects in patients with ARPC1B germline mutations account for combined immunodeficiency

Blood (2018) 132 (22): 2362–2374.

https://doi.org/10.1182/blood-2018-07-863431

Published: 2018

Includes: Supplemental data

NARROW

Combining CAR Engineering and CIS Checkpoint Deletion in NK Cells for the Treatment of B Cell Hematologic Malignancies

CLL Increases the Frequency of CD4 + HLADR + PD1 + T Cells That Demonstrate an Exhaustion Gene Signature and Potential Prognostic Value for Disease Progression

Investigation of Cell-Contact Dependent Alterations in Immune Synapse Formation between T Cells and BCP-ALL Cells

Blinatumomab-Induced T Cell Activation at Single Cell Transcriptome Resolution

Generation of a Highly Sensitive CD22 CAR

The IRE1-XBP1s Pathway Impairment Underpins NK Cell Dysfunction in Hodgkin Lymphoma, That Is Partly Restored By PD-1 Blockade

EZH2 Gain-of-Function Mutations Generate a Lymphoma-Permissive Immune Niche

Ibrutinib-Based Therapy Improves Anti-Tumor T Cell Killing Function Allowing Effective Pairing with Anti-PD-L1 Immunotherapy Compared to Traditional FCR Chemoimmunotherapy; Implications for Therapy and Correlative Immune Functional Data from the Phase III E1912 Trial

AMV564, a Bivalent Bispecific (2×2) CD33/CD3 T-Cell Engager, Is Active and Improves Survival in a Mouse Model of Acute Myeloid Leukemia

Eliciting Anti-Tumor T Cell Immunity in Chronic Lymphocytic Leukemia (CLL) with PD-L1/PD-1 Blockade Is Enhanced By Avadomide Immunotherapy through the Triggering of Immunogenic Interferon Signaling

Functional Status Is Associated with Outcomes after Allogeneic Stem Cell Transplantation for Older Patients with Hematologic Malignancies

Myeloma Patient-Derived Bone Marrow Serum Negatively Regulates Natural Killer Cell Activity

Longitudinal High-Throughput T Cell Repertoire Profiling of Chronic Lymphocytic Leukemia Patients Under Different Types of Treatment: Implications for Combination Strategies

Thrombin Generation Impairments in Platelet Function Disorders

PD-1 Overexpression in Richter's Transformation (RT) and Aggressive Chronic Lymphocytic Leukemia (CLL) after Progression on Ibrutinib Increases Bcl-2 Expression Via Akt/mTOR Pathway

Axl-RTK Inhibition Modulates T Cell Functions and Synergizes with Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies

Modulation of T-Cell Function and Immune Phenotype in the Microenvironment of Emu-TCL1 CLL Bearing Mice By Ibrutinib

Modulation of T-Cell Function in the Microenvironment of Emu-TCL1 CLL Bearing Mice By Btki Appears Independent of ITK

An expanding network of cytoskeletal defects

T-cell defects in patients with ARPC1B germline mutations account for combined immunodeficiency

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only